Export

Efavirenz + lamivudine + tenofovir
Essential medicine status
General description
A fixed-dose combination of two nucleoside reverse-transcriptase inhibitors (NRTIs, lamivudine and tenofovir disoproxil fumarate) and a non-nucleoside reverse transcriptase inhibitor (NNRTI, efavirenz) for treatment of human immunodeficiency virus (HIV) disease.
INN
Efavirenz + lamivudine + tenofovir
Medicine type
Chemical agent
Therapeutic equivalent for
Recommendations
Section
Fixed-dose combinations of antiretrovirals
  • Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)